Sullivan & Cromwel represented SK Bioscience in the transaction. South Korea-based vaccine developer SK Bioscience has agreed to acquire, through its German subsidiary, a 60 percent...
SK Bioscience’s Acquisition of IDT Biologika
SK bioscience’s $84.5 Million Equity Investment in Novavax
Milbank represented SK bioscience Co. Ltd. in the deal. SK bioscience announced that its board of directors decided to make an equity investment in Novavax, securing...